Human Albumin
Commercial- Indications
- Critical care
Company intelligence / Profile preview
BPL Plasma collects human plasma at over two dozen US centers. The plasma supports the manufacture of commercialized life-saving biologic therapies for rare and serious conditions such as primary immunodeficiencies and hereditary bleeding disorders. Its parent company has developed the first and only approved treatment for a specific rare hereditary deficiency affecting blood clotting.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BPL Plasma.